Skip to content

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Response to SMAC mimetics in patient-derived models of triple-negative breast cancer relies on RIPK1 activation

Triple-negative breast cancer (TNBC) is a highly metastatic and aggressive breast cancer subtype with limited targeted treatment options. Second mitochondrial activator of caspases (SMAC) mimetics represent a promising therapeutic class for TNBC patients, although they have yet to be approved clinically. Screening a re...

E. Brown, Paige Jensen, Chieh-Hsiang Yang et al. · 0 citations
Open access Oct 2026

FORESEE: A prospective feasibility trial of functional precision oncology for metastatic breast cancer patients

The FORESEE trial (NCT04450706) was a prospective study to evaluate the feasibility of integrating organoid-based drug testing with comprehensive genomic characterization to inform treatment selection in patients with HER2-negative metastatic breast cancer. The primary objective of the study was to determine the feasib...

C. Vaklavas, S. Buys, S. D. Scherer et al. · 0 citations
Open access Aug 2026

Determination of drug sensitivity in patient derived models of breast cancer by multiparametric quantitative phase imaging

Functional precision oncology aims to guide therapy selection by directly measuring drug sensitivity in patient-derived cancer samples. However, most existing functional assays require prolonged cell expansion limiting their feasibility for time-sensitive clinical decision-making. We evaluated whether multiparame...

Edward R. Polanco, Tarek E. Moustafa, Ozlen Balcioglu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.